v3.26.1
Acquisitions, divestitures and other arrangements - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 6 Months Ended 24 Months Ended
Dec. 26, 2025
Apr. 02, 2025
Sep. 27, 2026
Mar. 29, 2026
Jun. 28, 2026
Jun. 29, 2025
Jan. 02, 2028
Dec. 28, 2025
Business Combination [Line Items]                
Payments to acquire businesses       $ 17,500 $ 263 $ 14,458    
Acquisition related costs         100 $ 200    
Goodwill (Note 3)         48,479     $ 48,772
Royalty Pharma plc.                
Business Combination [Line Items]                
Milestone payments receivable         $ 500      
Scenario, Forecast                
Business Combination [Line Items]                
Other commitment, maximum funds to receive             $ 500  
Halda Therapeutics                
Business Combination [Line Items]                
Payments to acquire businesses $ 3,050              
Acquisition related costs 200              
Assets acquired including goodwill 3,400              
Goodwill (Note 3) 600              
Liabilities assumed 600              
Halda Therapeutics | In-process research and development                
Business Combination [Line Items]                
Asset acquired, identifiable intangible asset, indefinite-lived $ 2,800              
Intra-Cellular Therapies, Inc.                
Business Combination [Line Items]                
Acquisition related costs   $ 400            
Goodwill (Note 3)   2,900            
Liabilities assumed   $ 3,000            
Share price (in dollars per share)   $ 132.00            
Consideration transferred   $ 14,500            
Integration-related cost, expense   100            
Assets acquired   17,500            
Amortizable intangibles asset   5,200            
Business combination, other asset   1,100            
Intra-Cellular Therapies, Inc. | In-process research and development                
Business Combination [Line Items]                
Asset acquired, identifiable intangible asset, indefinite-lived   $ 8,300            
Firefly Bio, Inc. | Scenario, Forecast                
Business Combination [Line Items]                
Business acquisition cost     $ 1,000